Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China.
OBJECTIVES Lenacapavir, a first-in-class, long-acting capsid inhibitor (CAI), has been approved for HIV-1 treatment and prevention. However, naturally occurring resistance to the HIV-1 CAI at the quasi-species level is rarely reported. METHODS Using next-generation sequencing (NGS), we obtained 495 HIV-1 near-full-le...